Related Experiment Videos
Lupus myocarditis: marked improvement in cardiac function after intravenous immunoglobulin therapy
Vikas Suri1, Subhash Varma, Kiran Joshi
1Post Graduate Institute of Medical Eduction and Research, Chandigarh, India.
Intravenous immunoglobulin (IVIg) is emerging as the mainstay in the treatment of many autoimmune diseases, including systemic lupus erythematosus. IVIg has been found to be beneficial in myocarditis due to dermatomyositis/polymyositis, Kawasaki disease, and viral myocarditis in children. We report an 18-year-old man of active lupus with worsening cardiac systolic function who did not respond to pulse methylprednisolone and cyclophosphamide, but subsequently showed an improvement in his cardiac function after IVIg administration.
Intravenous immunoglobulin (IVIg) is emerging as the mainstay in the treatment of many autoimmune diseases, including systemic lupus erythematosus. IVIg has been found to be beneficial in myocarditis due to dermatomyositis/polymyositis, Kawasaki disease, and viral myocarditis in children. We report an 18-year-old man of active lupus with worsening cardiac systolic function who did not respond to pulse methylprednisolone and cyclophosphamide, but subsequently showed an improvement in his cardiac function after IVIg administration.
Related Concept Videos
Myocarditis III: Medical Management
Myocarditis IV: Nursing Management
Cardiomyopathy V: Interprofessional Care
Myocarditis II: Clinical Features and Diagnostic Tests
Myocarditis I: Introduction
Pericarditis III: Medical Management